trial

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

NCTId NCT01688037
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 109 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2013-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
109 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-09
Primary completion
2013-09
Eligibility
ALL · 18 Years · 85 Years

Interventions & indications

Drugs
NBI-98854

Sponsors

Neurocrine BiosciencesLead Sponsor

Investigators

1
Chris O'Brien, MDStudy Director

Sites

0 total

Linked catalysts

1
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia — primary completion2013-09

Facts & assertions

4 sourced
Enrollment
109
Phase
PHASE2
Primary Completion Date
2013-09
Status
COMPLETED
relationships
The graph out of here
drug
NBI-98854
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Tardive Dyskinesia
indication
Tardive Dyskinesia
indication
investigator
Chris O'Brien, MD
person